Peptides Recovery & Healing Preclinical (animal) data

BPC-157

Body Protection Compound

4.1 hours

Half-life

0.25–1 mg

Typical dose

2–6 weeks

Cycle length

Gastric-derived peptide widely used off-label for tendon, ligament, and gut healing research.

Key takeaways

Animal studies show accelerated tendon, ligament, and gut healing — but no published human clinical trials exist.
Reported protocols cluster around 250–500 mcg once or twice daily, injected subcutaneously near the injury site.
Half-life is estimated at under 30 minutes from animal PK work; the numbers in the plotter are research-derived estimates, not human measurements.
Not an approved medication — source quality (COA) and sterile reconstitution are the main practical risks.

Overview

What it is

BPC-157 (body protection compound 157) is a 15-amino-acid synthetic peptide derived from a sequence found in human gastric juice. Animal models show it promotes angiogenesis (new blood vessel formation), accelerates tendon and ligament repair, and protects gut mucosa through nitric oxide and growth factor pathways. Unlike most peptides, it also shows oral activity in animal studies, though subcutaneous injection remains the more common research route.

Pharmacokinetics

There is no human PK data. Animal work puts the elimination half-life under 30 minutes, and the values shown in the plotter are research-derived estimates from animal data and analog peptide behavior, not human measurements.

What the evidence says

Everything rests on preclinical work: no published human clinical trials exist, and the dosing numbers repeated online trace back to animal-to-human dose conversions. BPC-157 is not an approved medication. Source quality verification (COA) and sterile reconstitution technique are the critical harm-reduction priorities.

Reported dosing protocols

Protocols reported in research literature and clinic/community use — informational context, not a dosing recommendation.

Use case	Dose	Route	Frequency	Duration
Tendon / ligament / joint	250–500 mcg	SubQ or IM near injury	1–2× daily	2–4 weeks (up to 6 post-op)
Gut / GI support	250–500 mcg	Oral or SubQ	1–2× daily	4–6 weeks
Nerve / systemic	200–500 mcg	SubQ	Once daily	4+ weeks

Pharmacokinetic summary

Model tier: Simple (t½ + F, Tmax estimated)
Half-life: 4.1 hours
Bioavailability: 60%
Typical dose: 0.25–1 mg

Frequently asked questions

Is BPC-157 FDA-approved?

No. It is sold as a research chemical and has no approved human use. Most dosing numbers online trace back to animal studies converted to rough human equivalents, then repeated across forums until they look established — repetition is not confirmation.

Oral or injectable BPC-157 — what's the difference?

BPC-157 is unusual in showing oral activity in animal studies, so oral use is common for gut-related goals. For musculoskeletal repair, subcutaneous injection (often near the injury site) is the more common research route. There is no strong comparative human data showing which route works better for a given goal.

How long does a BPC-157 cycle last?

Reported protocols run 2–4 weeks for minor soft-tissue issues and 4–6 weeks for gut or post-surgical goals. There is no established taper requirement — it does not suppress endogenous hormones.

What does BPC-157 stack with?

The most common pairing is TB-500 (the "Wolverine stack"): BPC-157 is framed as localized repair while TB-500 supports systemic healing and cell migration. Some add GH secretagogues like CJC-1295/ipamorelin for broader recovery support.

References

Estimated (limited human PK) — Gastric-derived pentadecapeptide; human PK poorly characterized.
Vukojević et al., Biomedicines 2022 — BPC-157 pharmacokinetics review — Proposed 200 µg/day human dose converted from 20 µg/kg rat studies; elimination half-life <30 min in rats/dogs.
Sikiric et al., Current Pharmaceutical Design 2020 — Review of BPC-157 cytoprotection and fistula/wound-healing evidence (animal models).
Seiwerth et al., Current Pharmaceutical Design 2020 — BPC-157 rescues NSAID-induced intestinal permeability damage in rats (GI protection model).
Gwyer et al., Cell and Tissue Research 2019 — BPC-157 and accelerated musculoskeletal soft-tissue healing (review of animal models).

Related compounds

TB-500 (Thymosin Beta-4)

Synthetic version of thymosin beta-4 involved in tissue repair, angiogenesis, and recovery.

TB-500 Fragment

Short active fragment of thymosin beta-4 intended to retain the healing motif with faster clearance.

ARA-290 (Cibinetide)

Peptide analog of the erythropoietin helix B region studied for neuropathy and tissue protection.

Comments

Loading comments…